SmithKline Beecham Pharmaceuticals

SmithKline Beecham was a prominent British pharmaceutical company formed in 1989 through the merger of SmithKline Beckman and the Beecham Group. The company was a global leader in several therapeutic areas, most notably in anti-infectives, central nervous system disorders, and vaccines. Key products developed or marketed by the firm included the antidepressant Paxil, the antibiotic Augmentin, and the diabetes medication Avandia. In December 2000, SmithKline Beecham merged with Glaxo Wellcome in a deal valued at approximately $76 billion to form GlaxoSmithKline (now GSK). This merger created one of the largest healthcare companies in the world, consolidating significant R&D capabilities and a vast commercial portfolio. The legacy of SmithKline Beecham continues to underpin GSK's dominant position in the global vaccine market and its extensive respiratory franchise.